Therapeutic potential of "rexinoids" in cancer prevention and treatment

Takemi Tanaka, Luigi M De Luca

Research output: Contribution to journalArticle

Abstract

Retinoid X receptor (RXR) is a combinatorial partner for one third of the 48 human nuclear receptor superfamily members and acts as a master coordinator of nuclear receptor signaling pathways involved in the control of cell growth and differentiation. Thus, ligand-dependent simultaneous activation of multiple pathways is an attractive strategy for molecular-targeted therapy of neoplastic disease. However, clinical trials in RXR-targeted molecular therapy with the RXR ligand (rexinoid) have yielded disappointing outcomes. In this review, we discuss a possible mechanism underlying the loss of sensitivity to rexinoid therapy.

Original languageEnglish (US)
Pages (from-to)4945-4947
Number of pages3
JournalCancer Research
Volume69
Issue number12
DOIs
StatePublished - Jun 15 2009

Fingerprint

Retinoid X Receptors
Molecular Targeted Therapy
Cytoplasmic and Nuclear Receptors
Ligands
Neoplasms
Cell Differentiation
Therapeutics
Clinical Trials
Growth

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Therapeutic potential of "rexinoids" in cancer prevention and treatment. / Tanaka, Takemi; De Luca, Luigi M.

In: Cancer Research, Vol. 69, No. 12, 15.06.2009, p. 4945-4947.

Research output: Contribution to journalArticle

@article{13a5b79868b1427c8e38c17696c9aa9f,
title = "Therapeutic potential of {"}rexinoids{"} in cancer prevention and treatment",
abstract = "Retinoid X receptor (RXR) is a combinatorial partner for one third of the 48 human nuclear receptor superfamily members and acts as a master coordinator of nuclear receptor signaling pathways involved in the control of cell growth and differentiation. Thus, ligand-dependent simultaneous activation of multiple pathways is an attractive strategy for molecular-targeted therapy of neoplastic disease. However, clinical trials in RXR-targeted molecular therapy with the RXR ligand (rexinoid) have yielded disappointing outcomes. In this review, we discuss a possible mechanism underlying the loss of sensitivity to rexinoid therapy.",
author = "Takemi Tanaka and {De Luca}, {Luigi M}",
year = "2009",
month = "6",
day = "15",
doi = "10.1158/0008-5472.CAN-08-4407",
language = "English (US)",
volume = "69",
pages = "4945--4947",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Therapeutic potential of "rexinoids" in cancer prevention and treatment

AU - Tanaka, Takemi

AU - De Luca, Luigi M

PY - 2009/6/15

Y1 - 2009/6/15

N2 - Retinoid X receptor (RXR) is a combinatorial partner for one third of the 48 human nuclear receptor superfamily members and acts as a master coordinator of nuclear receptor signaling pathways involved in the control of cell growth and differentiation. Thus, ligand-dependent simultaneous activation of multiple pathways is an attractive strategy for molecular-targeted therapy of neoplastic disease. However, clinical trials in RXR-targeted molecular therapy with the RXR ligand (rexinoid) have yielded disappointing outcomes. In this review, we discuss a possible mechanism underlying the loss of sensitivity to rexinoid therapy.

AB - Retinoid X receptor (RXR) is a combinatorial partner for one third of the 48 human nuclear receptor superfamily members and acts as a master coordinator of nuclear receptor signaling pathways involved in the control of cell growth and differentiation. Thus, ligand-dependent simultaneous activation of multiple pathways is an attractive strategy for molecular-targeted therapy of neoplastic disease. However, clinical trials in RXR-targeted molecular therapy with the RXR ligand (rexinoid) have yielded disappointing outcomes. In this review, we discuss a possible mechanism underlying the loss of sensitivity to rexinoid therapy.

UR - http://www.scopus.com/inward/record.url?scp=67449132372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67449132372&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-08-4407

DO - 10.1158/0008-5472.CAN-08-4407

M3 - Article

VL - 69

SP - 4945

EP - 4947

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 12

ER -